WO-2011060746 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
may give you the structure
May 9, 2013
Hutchison Chi-Med expects to license global rights to fruqintinib, one of its novel small-cell cancer drugs, before year-end, according to CEO Christian Hogg.
The company has been in due diligence discussions with potential partners, he added. Because the drug is a promising treatment for solid tumors,
Chi-Med will conduct simultaneous clinical trials against several types of cancer, and the company wants a partner to help shoulder the financial burden
Hutchison China MediTech Ltd. (HCM), the drugmaker controlled by Hong Kong billionaire Li Ka-shing, is in talks to license a cancer treatment based on traditional Chinese medicines, Chief Executive Officer Christian Hogg said.
The Hong Kong-based company, known as Chi-Med, completed due diligence with potential partners and will probably reach an agreement on fruquintinib by year-end, Hogg said yesterday…
View original post 167 more words
